DE60114852T2 - Chinazolin-derivate als alpha-1 adrenerge antagonisten - Google Patents

Chinazolin-derivate als alpha-1 adrenerge antagonisten Download PDF

Info

Publication number
DE60114852T2
DE60114852T2 DE60114852T DE60114852T DE60114852T2 DE 60114852 T2 DE60114852 T2 DE 60114852T2 DE 60114852 T DE60114852 T DE 60114852T DE 60114852 T DE60114852 T DE 60114852T DE 60114852 T2 DE60114852 T2 DE 60114852T2
Authority
DE
Germany
Prior art keywords
methyl
alkyl
amino
compound
methylamino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60114852T
Other languages
German (de)
English (en)
Other versions
DE60114852D1 (de
Inventor
Kephra Cyrus BECKER
Richard Chris MELVILLE
Roland Juerg PFISTER
Xiaoming Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of DE60114852D1 publication Critical patent/DE60114852D1/de
Application granted granted Critical
Publication of DE60114852T2 publication Critical patent/DE60114852T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE60114852T 2000-08-31 2001-08-23 Chinazolin-derivate als alpha-1 adrenerge antagonisten Expired - Fee Related DE60114852T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22950300P 2000-08-31 2000-08-31
US229503P 2000-08-31
PCT/EP2001/009749 WO2002018348A2 (en) 2000-08-31 2001-08-23 Quinazoline derivatives as alpha-1 adrenergic antagonists

Publications (2)

Publication Number Publication Date
DE60114852D1 DE60114852D1 (de) 2005-12-15
DE60114852T2 true DE60114852T2 (de) 2006-07-27

Family

ID=22861517

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60114852T Expired - Fee Related DE60114852T2 (de) 2000-08-31 2001-08-23 Chinazolin-derivate als alpha-1 adrenerge antagonisten

Country Status (19)

Country Link
US (1) US6559153B2 (enExample)
EP (1) EP1315714B1 (enExample)
JP (1) JP3971299B2 (enExample)
KR (1) KR100602929B1 (enExample)
CN (1) CN1308324C (enExample)
AR (1) AR032475A1 (enExample)
AT (1) ATE309240T1 (enExample)
AU (2) AU2001293788B2 (enExample)
BR (1) BR0113585A (enExample)
CA (1) CA2420177C (enExample)
DE (1) DE60114852T2 (enExample)
ES (1) ES2251512T3 (enExample)
GT (1) GT200100181A (enExample)
MX (1) MXPA03001777A (enExample)
PA (1) PA8527901A1 (enExample)
PE (1) PE20020407A1 (enExample)
UY (1) UY26919A1 (enExample)
WO (1) WO2002018348A2 (enExample)
ZA (1) ZA200301082B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60215195T2 (de) * 2001-08-10 2007-08-23 Monash University, Clayton Derivate morphinähnlicher opioidverbindungen
ATE521593T1 (de) * 2002-04-03 2011-09-15 Orion Corp Verwendung eines alfa2-adrenorezeptorantagonisten bei mit dem zns zusammenhängenden erkrankungen
TW200403058A (en) * 2002-04-19 2004-03-01 Bristol Myers Squibb Co Heterocyclo inhibitors of potassium channel function
ITMI20030151A1 (it) * 2003-01-30 2004-07-31 Recordati Ind Chimica E Farma Ceutica S P A Uso di antagonisti selettivi del recettore mglu5 per il trattamento di disfunzioni neuromuscolari del tratto urinario inferiore.
DE602004022819D1 (de) * 2003-06-06 2009-10-08 Vertex Pharma Von atp-bindende kassette transportern
ES2326979T3 (es) * 2003-07-24 2009-10-22 Euro-Celtique S.A. Compuestos de piperidina y composiciones farmaceuticas que contienen a los mismos.
WO2006021345A2 (en) * 2004-08-27 2006-03-02 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with adrenergic alpha-1b receptor (adra1b)
MY179032A (en) 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
US7413607B2 (en) * 2005-03-31 2008-08-19 3M Innovative Properties Company Templated semiconductor particles and methods of making
US7344583B2 (en) * 2005-03-31 2008-03-18 3M Innovative Properties Company Methods of making metal particles within cored dendrimers
DE602006010540D1 (de) 2005-05-04 2009-12-31 Hoffmann La Roche (3,4-dihydro-chinazolin-2-yl)-(2-aryloxy-ethyl)-amine mit aktivität am 5-ht-rezeptor
DK3719018T3 (da) 2006-04-25 2025-09-29 Astex Therapeutics Ltd Purin og deazapurinderivater som farmaceutiske forbindelser
US7956001B2 (en) * 2006-09-19 2011-06-07 3M Innovative Properties Company Templated metal oxide particles and methods of making
BRPI0818533B8 (pt) 2007-10-11 2021-05-25 Astrazeneca Ab composto, composição farmacêutica, uso de um composto, e, processo para a preparação de um composto
TW200944526A (en) * 2008-04-22 2009-11-01 Vitae Pharmaceuticals Inc Carbamate and urea inhibitors of 11β-hydroxysteroid dehydrogenase 1
DK2694056T3 (da) 2011-04-01 2020-01-02 Astrazeneca Ab Terapeutisk behandling
PL2785349T5 (pl) 2011-11-30 2023-01-30 Astrazeneca Ab Kombinacja do leczenia nowotworu
AU2013204533B2 (en) 2012-04-17 2017-02-02 Astrazeneca Ab Crystalline forms
WO2018169818A1 (en) * 2017-03-12 2018-09-20 Xiaodong Wang Polycyclic amines as opioid receptor modulators
WO2019088095A1 (ja) * 2017-11-02 2019-05-09 国立大学法人九州大学 鎮痛剤及びその使用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2232138A1 (en) 1995-09-29 1997-04-03 William C. Lumma Alpha 1b adrenergic receptor antagonists
GB9526546D0 (en) * 1995-12-23 1996-02-28 Pfizer Ltd Compounds useful in therapy
GB9700504D0 (en) 1997-01-11 1997-02-26 Pfizer Ltd Pharmaceutical compounds
US6355641B1 (en) 1999-03-17 2002-03-12 Syntex (U.S.A.) Llc Oxazolone derivatives and uses thereof

Also Published As

Publication number Publication date
MXPA03001777A (es) 2003-06-04
JP3971299B2 (ja) 2007-09-05
AU9378801A (en) 2002-03-13
WO2002018348A2 (en) 2002-03-07
AU2001293788B2 (en) 2007-10-11
DE60114852D1 (de) 2005-12-15
US6559153B2 (en) 2003-05-06
PE20020407A1 (es) 2002-05-21
ZA200301082B (en) 2004-05-07
UY26919A1 (es) 2002-02-28
WO2002018348A3 (en) 2002-07-11
ATE309240T1 (de) 2005-11-15
BR0113585A (pt) 2003-07-29
PA8527901A1 (es) 2002-07-30
CA2420177C (en) 2008-07-08
CN1545510A (zh) 2004-11-10
GT200100181A (es) 2002-05-23
CA2420177A1 (en) 2002-03-07
CN1308324C (zh) 2007-04-04
KR20030022421A (ko) 2003-03-15
US20020045614A1 (en) 2002-04-18
ES2251512T3 (es) 2006-05-01
KR100602929B1 (ko) 2006-07-20
EP1315714A2 (en) 2003-06-04
AR032475A1 (es) 2003-11-12
JP2004507527A (ja) 2004-03-11
EP1315714B1 (en) 2005-11-09

Similar Documents

Publication Publication Date Title
DE60114852T2 (de) Chinazolin-derivate als alpha-1 adrenerge antagonisten
DE60308670T2 (de) Substituierte indole als alpha-1 agonisten
DE60106607T2 (de) Substituierte 1-aminoalkyl-lactame und ihre verwendung als muscarinrezeptor antagonisten
DE60110844T2 (de) Chinazolone derivate als alfa 1a/b adrenozeptor antagonisten
DE60224404T2 (de) Substiuierte piperidine als melanocortinrezeptormodulatoren
DE69921351T2 (de) 4-Aroyl-Piperidin-CCR-3 Rezeptorantagonisten III
DE60218037T2 (de) Neue indolderivate mit affinität zum 5-ht6-rezeptor
DE60212841T2 (de) 4 piperazinylindolderivate mit affinität zum 5-ht6-rezeptor
DE69722220T2 (de) 4-substituierte beta-carboline als immunomodulatoren
DE69935600T2 (de) Dihydrobenzodioxincarbonsäureamid- und ketonderivate als 5-ht4-rezeptorantagonisten
DE60114413T2 (de) Substituierte 1-aminoalkyl-lactame und deren verwendung als muscarinrezeptor-antagonisten
EP1140898B1 (de) Amid- und harnstoffderivate als 5-ht reuptakeinhibitoren und als 5-ht1b/1d liganden
WO2004012648A2 (de) Substituierte diarylheterocyclen, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DE60010596T2 (de) Pyridinderivate, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zubereitungen
EP0459256B1 (de) Oxazolidinone mit ZNS-dämpfender Wirkung
DE69721742T2 (de) N-substituierte 4-((4'-aminobenzoyl)-oxymethyl)-piperidine mit gastrokinetischen eigenschaften
AU2001293788A1 (en) Quinazoline derivatives as alpha-1 adrenergic antagonists
DE60313895T2 (de) 2,7-disubstituierteindole und ihre verwendung als 5-ht6 modulatoren
DE60224221T2 (de) Aminotetralinderivate, antagonisten von muscarinrezeptoren
DE602004007387T2 (de) 5-substituierte chinazolinonderivate
DE60017446T2 (de) Isochinolin- und Chinazolinderivate mit kombinierter 5-HT1A-, 5-HT1B- und 5-HT1D- Rezeptoraffinität
DE69612753T2 (de) (r)-5-bromo-n-(1-ethyl-4-methylhexahydro-1h-1,4-diazepin-6-yl)-2-methoxy-6-methylamino-3-pyridincarboxamid, verfahren zu seinerherstellung und dieses enthaltende medizinische zubereitung
DE69820066T2 (de) Piperazinderivate zur behandlung der niedrigen harnwege
CZ292847B6 (cs) Derivát benzamidu, způsob jeho přípravy a použití, farmaceutická kompozice na jeho bázi a způsob její přípravy
DE69637412T2 (de) Prokinetisch wirksame oxadiazole

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee